Contreras Decker (sheeplan6)

LDRT is a cost-effective non-toxic treatment already available in most general hospitals. This fact allows that it would be used for the large number of patients that will suffer this disease, and that would not receive specific anti-IL-6 treatments in ICUs in low and middle income countries. © 2020 Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.Background and purpose Taste impairment is a common radiation-induced toxicity in head and neck cancer (HNC) patients acutely. However, data on the potential for recovery and the time dependent course of late taste impairment are limited. Materials and methods As part of an IRB-approved observational prospective study, HNC patients underwent serial surveys including the MD Anderson Symptom Inventory - Head and Neck module (MDASI-HN). For our analysis, we extracted MDASI-HN taste item results from oropharyngeal cancer patients treated with intensity-modulated radiotherapy or volumetric modulated arc therapy and at least two taste assessments after ≥1 year from end of radiotherapy (RT). Results 1214 MDASI taste items from 326 patients between 1 and 13 years post-RT were included. Median prescribed dose to the high-dose clinical target volume (CTV1) was 66.0 Gy, with 180 patients (55%) receiving chemotherapy. Taste markedly improved in the first years from end of RT, but plateaued after year 5. In patients with taste assessment in subsequent years, a significant reduction in taste impairment was found from the second to the third year (p = 0.001) and tended towards significance from the third to the fourth year (p = 0.058). Multivariate analysis revealed treatment site as significant factor in the sixth year from RT and CTV1 dose and age in the seventh year. Conclusion Radiation-induced taste impairment may improve over an extended time interval, but becomes relatively stable from year 5 post-RT. Direct characterization of RT-induced taste impairment and the calculation of normal tissue complication probability should include consideration of the time-dependent course in taste recovery. © 2020 The Authors.Mycobacterium shinjukuense is a newly identified nontuberculous mycobacteria (NTM) and its gene sequence of 16S rRNA shows high homology to that of Mycobacterium tuberculosis. We present a case of M. shinjukuense pulmonary disease progressed to pleuritis after iatrogenic pneumothorax. The patient was initially diagnosed as tuberculosis based on a positive result for the 16S rRNA of an M. tuberculosis identification kit using scrapings from the cavitary nodule. We need to bear in mind that pneumothorax following bronchoscopy may induce NTM pleuritis and M. learn more shinjukuense infection should be considered in the differential diagnosis of mycobacterial pulmonary disease with effusion. © 2020 The Authors.Background and Objectives Most people agree that cognitive capabilities are an integral component of wisdom and its development. However, a question that has received less attention is whether people view maintaining cognitive capabilities as a necessary prerequisite for maintaining wisdom. Research Design and Methods This study used a mixed-methods approach to evaluate people's views about the relationship between age-related cognitive declines, Alzheimer's disease (AD), and wisdom. Our final sample of 1,519 adults ranged in age from 18 to 86. Results The majority of participants stated that wisdom could be present even in people with significant age-related cognitive declines or with AD. In the qualitative responses, common justifications for this were (a) that even people with severe AD can still exhibit wise behaviors during lucid moments, (b) that wisdom is an immutable characteristic that is impossible to lose, and (c) that wisdom maintenance and cognitive capability maintenance are separate constructs. Discussion and Implications Although prior research has examined implicit theories about the role of